Portola's Heart Bypass Drug Gets Closed Advisory Committee Session
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Cardiovascular and Renal Drugs Advisory Committee will discuss Portola Pharmaceuticals' thromboxane receptor antagonist PRT061103, intended to prevent cardiovascular problems in patients who have developed intolerance to aspirin.